论文部分内容阅读
目的系统评价复方阿嗪米特联合胃肠动力药治疗功能性消化不良(FD)的疗效。方法通过中国知网(CNKI),中国生物医学文献数据库(CBM),PubMed,EMBASE,Cochrane Library等数据库,检索有关复方阿嗪米特联合胃肠动力药对比单用胃肠动力药治疗FD的随机对照试验,应用RevMan 5.3软件行Meta分析。结果共23个研究,包括2 412例FD患者纳入分析。复方阿嗪米特联合胃肠动力药治疗FD的总有效率显著高于单用胃肠动力药(RR=1.38,95%CI=1.29-1.47)。各项研究均未报道严重不良反应。结论复方阿嗪米特联合胃肠动力药可明显提高FD的疗效,且安全性较高。
Objective To evaluate the efficacy of compound azinamid combined with gastrointestinal motility drug in the treatment of functional dyspepsia (FD). Methods A randomized controlled trial was conducted to search the randomized controlled trials on the combination of compound azinamater and gastrointestinal motility drug in the treatment of FD with single gastrointestinal motility drug through the CNKI, CBM, PubMed, EMBASE and Cochrane Library databases Control experiments, using RevMan 5.3 software Meta analysis. Results A total of 23 studies, including 2 412 FD patients, were included in the analysis. The total effective rate of compound azinamid combined with gastrointestinal motility in the treatment of FD was significantly higher than that of single gastrointestinal motility alone (RR = 1.38, 95% CI = 1.29-1.47). None of the studies reported serious adverse reactions. Conclusion Compound azinamid combined with gastrointestinal motility drug can significantly improve the efficacy of FD, and high safety.